Global Life Sciences Hiring Demand Increases 11.1% in Q2 2012
Global hiring within the ZRG Life Sciences Index was up 11.1% from the first quarter, finishing at 87.8, the second highest level over the last 9 quarters. Demand for new employees in Europe drove the index up globally as EMA reported a 34% increase in hiring levels overall. Medical device and diagnostics accounted for much of the growth, with over 1,300 new jobs sited in our index companies alone.
What’s Hot
- Europe is hiring! The EMA numbers are showing a new all-time high mark for total demand;
- Medical Device and Diagnostics is rebounding with a 22.8% increase in job opportunities around the world;
- Hiring for sales talent has returned with a 40% increase in sales talent opportunities within the index companies;
- Manufacturing roles jumped 100% in the quarter reflecting the trend of geographic shifts in where product is made around the world.
What’s Not
- Demand in Asia Pacific dropped by 11% in the quarter, perhaps reflecting a slowing growth rate;
- Quality, Regulatory and Clinical jobs dropped 16% from last quarter, although the total number of roles still remains robust;
- Research and Development Roles dipped 11%.
- Private Equity Investment in the sector is still off 50% from last year’s levels.
While EMA was the regional story, with a broad increase in hiring across medical device and pharma, one juggernaut is leading the charge. Novartis had a large increase in “job share” in this quarter’s index, with increased activities across all functions and regions in EMA. Driving hiring in the medical device and diagnostics in EMA was the big three led by Siemens, Philips and GE Medical. The America’s showed growth of 8% in new and open jobs in the quarter while APAC retreated 11.5%.
For a full copy of the report, go to www.zrgpartners.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
